他汀治疗对晚期心衰患者植入左心室辅助系统后神经系统事件的影响
本研究为单中心回顾性观察队列,纳入2008-2018年连续200例植入耐久性连续流左心室辅助系统(CF-LVAS)的成人患者,比较植入后是否使用他汀与后续神经系统事件的关系。结果显示他汀使用与神经系统事件发生率降低相关(年龄校正HR 0.46,95%CI 0.24-0.88,p=0.019),主要由缺血性卒中减少驱动,出血性卒中及其他安全性终点无显著差异。
要点
- CF-LVAS植入后使用他汀与神经系统事件风险降低相关(年龄校正HR 0.46)。
- 非HM3泵队列中他汀使用者缺血性卒中降低62%(年龄校正HR 0.38)。
- 出血性卒中及其他安全性终点在他汀使用与否间无显著差异。
核心结论
- CF-LVAS植入后处方他汀与较低的神经系统事件发生率相关,主要由缺血性卒中减少驱动。
- 研究提示多数已有他汀治疗指征的患者在CF-LVAS植入后或可继续使用他汀以降低缺血性卒中发生率。
研究设计与样本
- 单中心、回顾性、观察性队列研究,纳入2008-2018年10年间连续200例植入耐久性CF-LVAS的成人患者。
- 按泵植入后是否使用他汀分组比较,并按泵类型(HeartMate II、HeartWare HVAD、HeartMate 3)进行探索性分层分析。
主要发现
- 总体24%的CF-LVAS接受者发生至少1次神经系统事件。
- 他汀使用者神经系统事件率为0.11事件/患者年(EPPY),非使用者为0.22 EPPY(年龄校正HR 0.46;95%CI 0.24-0.88;p=0.019)。
- 不含HM3泵的队列中,他汀使用者缺血性卒中降低62%(0.05 vs 非使用者0.12 EPPY;年龄校正HR 0.38;95%CI 0.15-0.99;p=0.048)。
- 纳入HM3接受者分析时,缺血性卒中风险差异不显著(年龄校正HR 0.51;95%CI 0.22-1.21;p=0.13)。
- HM3 LVAS接受者的缺血性卒中率与接受非HM3 LVAS的他汀使用者相似(分别为0.06和0.05 EPPY)。
关键数值与推荐
- 他汀使用者神经系统事件率0.11 EPPY vs 非使用者0.22 EPPY(年龄校正HR 0.46;95%CI 0.24-0.88;p=0.019)。
- 非HM3队列缺血性卒中:他汀使用者0.05 EPPY vs 非使用者0.12 EPPY(年龄校正HR 0.38;95%CI 0.15-0.99;p=0.048)。
- 含HM3分析缺血性卒中:年龄校正HR 0.51;95%CI 0.22-1.21;p=0.13。
- HM3接受者缺血性卒中率0.06 EPPY,非HM3的他汀使用者0.05 EPPY。
- 出血性卒中及其他安全性终点按他汀使用无显著差异。
临床怎么用
- 对已有他汀治疗指征的CF-LVAS患者,植入后继续他汀治疗或有助于降低缺血性卒中发生率。
- 泵类型可能影响他汀与缺血性卒中的关联,HM3接受者中该关联不显著,需个体化评估。
局限性
- 单中心、回顾性、观察性设计,可能存在未测量混杂。
- 样本量为200例,按泵类型分层为探索性分析,亚组统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke is a leading cause of disability and death in advanced heart failure patients supported with a continuous-flow left ventricular assist system (CF-LVAS). Statins (HMG-CoA reductase inhibitors) reduce the risk of major cardiovascular and neurological events such as stroke, but their impact has not been evaluated in patients implanted with a CF-LVAS. We sought to explore the association between use of statin therapy and subsequent occurrence of neurological events, particularly stroke, following CF-LVAS implantation. METHODS: We performed a single center, retrospective, observational cohort study in 200 consecutive adults implanted with a durable CF-LVAS over a 10-year period (2008-2018). We compared patients according to statin use following pump implantation, stratified by an exploratory analysis of pump type (HeartMate II, HeartWare HVAD, and HeartMate 3 [HM3] LVAS). RESULTS: Overall, 24% of CF-LVAS recipients developed at least 1 neurological event, at a rate of 0.11 events per patient-year (EPPY) among those prescribed statins and 0.22 EPPY among non-users (age-adjusted hazard ratio [HR] 0.46; 95% confidence interval [CI],0.24-0.88; p = 0.019). In the cohort without the HM3 pump, ischemic strokes were 62% lower among statin users (0.05 versus 0.12 EPPY for non-users; age-adjusted HR, 0.38; 95% CI, 0.15-0.99; p = 0.048). The risk of ischemic stroke did not differ significantly when HM3 recipients were included in the analysis (age-adjusted HR, 0.51; 95% CI, 0.22-1.21; p = 0.13). However, ischemic stroke rate in HM3 LVAS recipients was similar to the rate in statin users who received a non-HM3 LVAS (0.06 and 0.05 EPPY, respectively). Rates of hemorrhagic stroke and other safety end points were not significantly different according to statin use. CONCLUSION: Statin prescription following CF-LVAS is associated with lower rates of neurological events, driven predominantly by a reduction in ischemic strokes. These findings suggest that most patients with a pre-existing indication for statin therapy may continue using statins following CF-LVAS in an effort to decrease the incidence of ischemic stroke.
引用
- Vieira JL, Pfeffer M, Claggett BL, et al. The impact of statin therapy on neurological events following left ventricular assist system implantation in advanced heart failure. J Heart Lung Transplant. 2020. PMID: 32220561. doi:10.1016/j.healun.2020.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。